Analyst Maintains Market Outperform Rating for Pharvaris with Increased Price Target
On January 23, 2024, JMP Securities analyst Jonathan Wolleben expressed his optimistic stance on Pharvaris (NASDAQ: PHVS) by maintaining a ...
Tag: PHVS
Pharvaris Receives FDA Approval to Proceed with Clinical Trials for Deucrictibant A Promising Step Towards Treating Hereditary Angioedema
As of January 22, 2024, an exciting announcement has been made regarding Pharvaris' investigational new drug application for deucrictibant. The ...
Popular News
-
Exploring the Rise of AI in Empowering Business and Personal Growth: Trends and Innovations
-
Trade Desk Shares Face Mounting Pressure as Tariff Warnings Materialize
-
Kraft Heinz Stock: A Contradiction in Market Sentiment
-
NextGen Healthcare Charts Course for Behavioral Health Transformation
-
Institutional Investors Rally Behind GXO Logistics
